0
Affimed NV
- 201-500 Employees
- Based in Heidelberg, Germany
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.
Social Media Links
Affimed NV
Most Recent Annual Report
MOST RECENT
2018 Annual Report
Affimed NV does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
